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Abstract
Introduction: Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) is defined when a loss of at 
least 30 dB occurs in over 3 continuous frequencies, in up to 72 hours, of which etiology is not 
established, despite adequate investigation. Different types of treatment regimens have been 
proposed, but only glucocorticoids have shown some evidence of benefit in the literature. 
Objective: To analyze whether the type of treatment or time  of treatment with glucocorticoids 
have any influence on hearing recovery in ISSHL. 
Methods: Observational retrospective cohort study. One hundred twenty-seven patients with ISSHL, 
treated at outpatient clinics between the years 2000 and 2010, were studied. We evaluated the 
prognostic correlation of the type of treatment and time to treatment with glucocorticoids and ISSHL. 
Results: The absolute hearing gain and the relative hearing gain was as follows: 23.6 dB and 
37.2%. Complete recovery was observed in 15.7% of patients, significant recovery in 27.6% 
and recovery in 57.5%.
Conclusion: In this study, there was no difference between the use and nonuse of glucocorti-
coids in hearing improvement. However, when started within seven days after onset, the use of 
glucocorticoids was a factor of better prognosis.
© 2014 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier 
Editora Ltda. All rights reserved.
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Influência dos corticosteroides no prognóstico auditivo da perda auditiva neurossensorial 
súbita idiopática
Resumo
Introdução: A perda auditiva neurossensorial súbita idiopática (PANSSI) é definida pela queda 
dos limiares auditivos tonais de, pelo menos, 30 dB em três frequências contíguas em até 72 
horas e apesar de uma investigação apropriada, a etiologia da lesão não é encontrada. Diversos 
tipos de tratamentos já foram idealizados para a PANSSI, no entanto, os corticosteroides são os 
que encontram as melhores evidências de efetividade na literatura. 
Please cite this article as: Bogaz EA, Suzuki FAB, Rossini BAA, Inoue DP, Penido NO. Glucocorticoid influence on prognosis of idiopathic 
sudden sensorineural hearing loss. Braz J Otorhinolaryngol. 2014;80:213-9. 
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Introduction
Sudden sensorineural hearing loss (SSHL) is defined when a 
loss of sensorineural thresholds of at least 30 dB occurs in 
over 3 continuous frequencies, within a period ranging from 
minutes of up to 72 hours.1,2 The incidence of SSHL ranges 
from 5 to 20 individuals per 100,000 people a year.2
When the investigation includes an etiological diagnosis, 
it is categorized as a case of SSHL with known cause and 
should receive special treatment, as in schwannomas, de-
generative diseases of the central nervous system (multiple 
sclerosis), syphilis, Lyme borreliosis and others. One must 
always seek to establish an etiology and specific treatment. 
The cases of undetermined etiology are classified as idio-
pathic sudden sensorineural hearing loss (ISSHL), and in this 
situation, there are some theories concerning the etiopa-
thology such as vascular injury, ruptured membranes of the 
inner ear, viral or bacterial infection, autoimmuneantibody 
lesion.3-6
Systemic corticosteroids have been used in clinical prac-
tice as a primary treatment of ISSHL; however, there is a 
lack of consistent data on its effectiveness.1,7,8 Corticoste-
roid therapy is started as early as possible, with high doses 
of the drug by oral or parenteral route, maintained for up 
to two weeks, after which it is gradually withdrawn. Sev-
eral other forms of treatment have been or are being used 
and studied, such as plasma expanders, carbogen, antiviral 
therapy, hyperbaric oxygen, antioxidants such as minerals 
and vitamins, but with less statistical evidence of efficacy 
than systemic corticosteroids.1,8-11
In addition to the doubt regarding the efficacy of corti-
costeroids in ISSHL, spontaneous recovery of hearing thresh-
olds occurs in 32% to 65% of cases according to Mattox et 
al.12 These patients would not likely benefit from the use of 
high doses of corticosteroids.
This study aims to evaluate the impact of time delay 
in initiating therapy with corticosteroids, and the type of 
treatment performed, on prognosis of hearing recovery in 
patients with ISSHL.
Methods
Patients were evaluated based on an observational retro-
spective cohort study. Individuals from the Outpatient Clinic 
of ISSHL, treated between 2000 and 2010 who had idiopath-
ic sudden sensorineural hearing loss were assessed. 
This study was approved by the Ethics Committee, under 
the CEP protocol number 0715/11.
Inclusion and exclusion criteria
Patients included in this study had unilateral ISSHL of at least 
30 dB in at least three consecutive frequencies occurring 
within 72 hours. They were treated at the Outpatient Clinic of 
ISSHL for at least 2 months and by that time exhibited hearing 
recovery stabilization, or normalization of hearing. Patients 
treated with different types of therapeutic approaches were 
followed. The standard treatment, when used, was oral pred-
nisone 1 mg/kg/day, with a maximum daily dose of 60 mg for 
at least 7 days, followed by gradual drug tapering.
Some patients received Pentoxifylline at a dose of 1,200 
mg/day divided into 3 doses for 2 months, either combined 
with corticosteroids or as a single treatment. Patients who 
did not receive any drug therapy had known contraindication 
to medication or refused treatment. Treatment with Pent-
oxifylline was used in the first years of this study and subse-
quently abandoned for lack of evidence of effectiveness.10
The study excluded patients with a history of middle and 
inner ear diseases and those whose etiology was defined as 
trauma, infection, Meniere disease, retrocochlear diseases, 
exposure to ototoxic drugs, perilymphatic fistula, barotrau-
ma, middle or inner ear malformations and history sugges-
tive of mumps, among others.
Bilateral cases, patients with intermittent hearing loss 
were also excluded, as were those with hearing loss in the con-
tralateral ear that prevented the calculation of recovery rates 
(contralateral loss higher than the current ISSHL), and those 
who started follow-up after 90 days of hearing loss onset.
Patient assessment
Patients who met the inclusion criteria underwent a de-
tailed history and otorhinolaryngological examination.
The following clinical data were analyzed: gender, date of 
hearing loss onset, concomitant symptoms such as tinnitus, 
vertigo, ear pain and ear fullness, presence of comorbidities, 
such as hypertension, diabetes mellitus, glaucoma, thyroid 
alterations and habits; drug use and audiometric parameters; 
previous episodes of hearing loss and family history.
Auditory assessment of patients was performed with 
an MA 41 audiometer, calibrated annually by a competent 
company, manufactured by DBA Maico Diagnostics, Minne-
Objetivo: Avaliar se o tipo de tratamento e o tempo de demora em iniciar o tratamento com 
corticosteroides têm correlação com a melhora dos limiares auditivos na PANSSI. 
Métodos: Estudo de coorte retrospectivo observacional. Foram avaliados 127 pacientes com 
PANSSI provenientes do ambulatório entre os anos de 2000 e 2010. Foi avaliada a correlação 
prognóstica do tipo de tratamento e tempo de demora para o início de tratamento e a PANSSI. 
Resultados: As taxas de recuperação absoluta e relativa foram 23,6 dB e 37,2% respectiva-
mente. Apresentaram melhora completa 15,7% dos pacientes, 27,6% apresentaram melhora 
significativa e 57,5% melhora. 
Conclusão: Neste estudo, não houve diferença entre o uso ou não de corticosteroide na melhora audi-
tiva. Contudo, quando iniciado até sete dias, o uso de corticosteroide foi fator de melhor prognóstico. 
© 2014 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Publicado por Elsevier 
Editora Ltda. Todos os direitos reservados.
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sota, USA. Initial audiometric thresholds were obtained, 
which coincided with the start of treatment/follow-up, as 
well as the final ones, with the latter being obtained after 
at least two months of the initial audiometry and hearing 
improvement had stabilized, or earlier in case of threshold 
normalization.
The patients were also submitted to laboratory tests 
that included blood count, measurement of lipids, serum 
fasting glucose, renal and thyroid function, erythrocyte sed-
imentation rate. Serological tests for syphilis, AIDS, Lyme 
borreliosis were also performed, when deemed necessary.
In suspected cases, screening for autoimmune diseases 
was performed. A total of 87 patients underwent magnetic 
resonance imaging of peripheral and central auditory path-
ways.
Calculating the means of affected frequencies
The arithmetic means of pure tone audiometry (PTA) were 
obtained at the beginning and end of follow-up in all pa-
tients, using the following method: arithmetic means of 
pure tones for each patient, according to the group of af-
fected frequencies. When low and middle frequencies were 
affected, the arithmetic means of 0.25, 0.5, 1 and 2 kHz 
were obtained; when middle and high frequencies were af-
fected, the arithmetic means of 1, 2, 3, 4, 6, 8 kHz were 
obtained; when only high frequencies were affected, the 
arithmetic means of 3, 4, 6 and 8 kHz were obtained; when 
low, middle and high frequencies were affected, the mean 
of all 8 frequencies was obtained. PTA was also calculated 
by averaging the frequencies affected in the contralateral 
ear of each patient, according to the frequency group of 
the affected ear. When severe hearing loss thresholds were 
not detected, the maximum audiometer threshold of 120 dB 
was considered as response.
Calculating recovery rates
To obtain the absolute and relative rates of hearing recov-
ery we took into account the non-affected side, according 
to the following formulas:
Absolute recovery rate of PTA (dB):
 (initial PTA in affected ear _ initial PTA in non- 
affected ear) _ (final PTA in affected ear _ final PTA in 
non-affected ear)
Relative recovery rate of PTA (%): 
(initial PTA in affected ear _ initial PTA in non-affected 
ear) _ (final PTA in affected ear _ final PTA in non-affect-
ed ear) × 100 / (initial PTA in affected ear _ initial PTA in 
non-affected ear).
Hearing improvement criteria by pure tone audiometry
For the analysis of hearing improvement, an increase in 
the arithmetic mean of pure tones (final PTA –initial PTA) 
was considered and the change in functional category, as 
follows: normal hearing and mild, moderate, severe and 
profound losses. 
Improvement: Change of functional category and im-
provement ≥ 15 dB.
Significant improvement: When there was improvement 
and the final hearing loss was mild. 
Complete improvement: When there was improvement 
and hearing thresholds returned to normal. (≤ 25 dB).
Treatment assessment
The following factors were evaluated in the treatment, 
based on the rates of hearing recovery and degree of im-
provement.
1. Type of treatment performed: 
Regarding the type of treatment performed, patients 
were categorized according to the drug used in treatment: 
corticosteroids alone; corticosteroid + Pentoxifylline, Pent-
oxifylline only and no treatment.
2. Time in days until the start of treatment:
Regarding the time for start of treatment, days until cor-
ticosteroid therapy start were considered, categorized as: 
up to 2 days, 3 to 7 days, 8 to 10 days, > 10 days, no treat-
ment. Patients who used Pentoxifylline only were allocated 
in the group without treatment.
There was no randomization for allocation of patients to 
the different treatment categories, which was decided based 
on clinical indication, as well contraindications, patient refusal, 
inability to treat and others. Patients were not matched by age, 
gender, presence of comorbidities, audiometric parameters, 
and other possible prognostic factors in group categorization.
Statistical methodology: the Chi-square tests were used, 
indicated to verify differences in the distribution of a cat-
egorized characteristic (2 or more categories) relative to 
another categorized characteristic, and ANOVA to compare 
3 or more groups of data with numerical measurement, with 
a statistical significance level of p < 0.05.
Results 
A total of 277 patients with sudden sensorineural hearing 
loss treated at the ISSHL Outpatient Clinic were assessed 
between 2000 and 2010. Of these, 8 patients did not meet 
the criteria for ISSHL definition. Ten patients had bilateral 
hearing loss and in 33 (12%) the hearing loss etiology was 
established. Seventy-five patients were lost to follow-up 
and informed consent for treatment information use was 
not obtained in 24. Thus, 127 patients that met the inclu-
sion criteria for unilateral ISSHL were included in the study.
The minimum age of the population was 12 and the max-
imum 82 years, with a mean of 48 years. Of the patients, 64 
were females and 63 males. The right side was involved in 
46.5% of cases and the left in 53.5%. Smoking was recorded 
in 11% of cases, hypertension in 34.6%, diabetes in 15% and 
dyslipidemia in 11%. The following were present in cases of 
personal history: disease in 9.4%, stroke in 2.4%, hypothy-
roidism in 6.3% and renal failure in 3.1%. Tinnitus was the 
most common associated symptom in 92.1% of cases.
Vertigo was observed in 52.8% of cases and 43.3% had ear 
fullness. A total of 87 patients underwent MRI assessment. 
The mean initial and final PTA and rates of hearing re-
covery in the sample are shown in Tables 1 and 2.
According to the criteria adopted, there was improve-
ment in 57.5%, a significant improvement in 27.6%, and full 
improvement in 15.7%.
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Table 1 Mean initial and final pure tone audiometry (PTA) 
values in ears (dB).
Initial PTA 
affected 
side
Final PTA 
affected 
side
Initial PTA 
normal 
side
Final PTA 
normal 
side
Mean  84.68   59.29 17.63 15.89
Median  83.75   60.00 16.25 14.37
Minimum  37.50    1.66  1.87  0.00
Maximum 120.00 120.00 52.50 54.37
SD  22.38 31.54 9.78 10.52
n 127 127 127 127
SD, standard deviation.
Table 3 Means of the initial and final PTA (dB) between the different types of treatment performed and ANOVA.
PTA of affected side
Type of treatment Initial Final
Mean 82.39 52.33
Corticosteroids only Standard deviation 23.10 31.43
n 33 33
Mean 85.60 58.10
Corticosteroids+Pentoxifylline Standard deviation 22.26 31.46
n 66 66
Mean 97.00 83.13
Pentoxifylline only Standard deviation 22.29 21.36
n 10 10
Mean 78.72 63.19
Notreatment Standard deviation 20.30 32.26
n 18 18
Table 4 ANOVA tests between categories of treatment for recovery rates.
Type of Treatment ANOVA Outcome
Corticosteroids 
only
Corticosteroids + 
Pentoxifylline
Pentoxifylline  
only No treatment p
Absolute PTA 
recovery 
(dB)
Mean 28.79 25.66 12.00 13.30
Standard deviation 27.64 23.34 12.45 20.52 0.052 Similar
n 33 66 10 18
Relative PTA 
recovery (%)
Mean 43.79 40.16 14.76 26.82
Standard deviation 39.08 35.09 13.96 38.94 0.075 Similar
n 33 66 10 18
Table 2 Mean rates of hearing recovery in the population.
Absolute PTA  
recovery in dB
Relative PTA  
recovery in (%)
Mean   23.64   37.21
Median   20.62   32.14
Minimum   -32.50a   -73.23a
Maximum 105.00 115.38
SD 24.04 36.23
n 127 127 
SD, standard deviation.  
aNegative values show poorer thresholds in relation to the initial one.
1. Type of treatment performed
PTA reduction and the rates of recovery were analyzed, 
taking into consideration the type of treatment (Tables 3 
and 4).
There was no statistically significant difference in PTA 
reduction and recovery rates in the different groups. How-
ever, there is statistical evidence that the groups that used 
corticosteroids had lower final PTA and higher recovery 
rates.
2. Time in days until start of treatment
It was observed that the initial PTA was statistically 
similar in the different ranges of days until the start of 
treatment. As for the absolute reduction in PTA, there was 
no statistical difference in the 3 groups that started treat-
ment in up to 10 days. There were smaller reductions in 
PTA for those who were treated after more than 10 days 
or had no treatment. For the absolute rate of hearing re-
covery, untreated cases showed less improvement than the 
ones that started treatment in up to 7 days.
For the relative rate of hearing recovery, patients who 
started treatment within 7 days had higher recovery than 
untreated ones or the ones that started treatment after 
seven days, with statistical significance. Patients that 
started treatment before 7 days showed PTA reduction 
with high significance (p < 0.0001) (Tables 5 and 6).
Effect   p-value
Treatment    0.0817
PTA (initial × final) < 0.0001
Treatment × PTA    0.0742
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Discussion
The interpretation and comparison of studies on treatment 
and prognostic factors in ISSHL remains a challenge to date, 
as most of them use different methodologies and criteria 
for evaluation of hearing recovery. Some studies evaluate 
PTA through three frequencies (0.5, 1, 2 kHz),12 4 frequen-
cies (0.5, 1, 2, 4 kHz),13 6 frequencies (0.25, 0.5, 1, 2, 4, 8 
kHz),14 and others use the mean of all frequencies. There 
are tests that assess only the mean of the frequencies af-
fected by hearing loss.15
In a previously performed study, which analyzed the dif-
ferent methodologies used in the assessment of ISSHL, In-
oue et al. found that when using the mean of 6 frequencies 
(0.25, 0.5, 1, 2, 4, 8 kHz), 8 frequencies (0.25, 0.5, 1, 2, 3, 
4, 6; 8 kHz) and affected frequencies, the same power of 
assessment is obtained, without statistical differences be-
tween these means.16 However, this same analysis did not 
compare the means of 3 and 4 frequencies, used in several 
studies in the past, which targeted low and middle frequen-
cies. The choice in this study was the use of PTA calculation 
through the affected frequencies, as we believe it is more 
representative individually, as it prevents disregarding the 
calculation of affected frequencies and also the inclusion of 
other non-affected frequencies, thus underestimating the 
extension of loss expressed by the mean.
Table 5 Means of the initial and final PTA (dB) for time (in days)until treatment start.
Moment
Time of treatment Initial Final
Mean 85.25 70.31
Notreatment Standard deviation 22.47 30.03
n 28 28
Mean 87.83 51.73
Up to 2 days Standard deviation 23.94 29.19
n 21 21
Mean 82.74 51.61
3 to 7 days Standard deviation 20.69 33.01
n 38 38
Mean 76.59 50.81
8 to 10 days Standard deviation 23.20 26.89
n 11 11
Mean 87.50 67.41
Morethan 10 days Standard deviation 23.54 30.99
n 29 29
Table 6 ANOVA tests between the categories of time in days until treatment start and hearing recovery rates.
Time of treatment ANOVA Outcome
No treat. Up to 2 days 2 to 7 days 8 to 10 days More than 10 days p
Absolute PTA 
recovery (dB)
Mean 12.83 33.98 29.85 24.02 18.35
Standard 
deviation
17.81 23.08 24.57 15.17 27.51 0.008
(No treat.) 
< (up to 2)  
= (2 to 7)
n 28 21 38 11 29
Relative PTA 
recovery (%)
Mean 22.51 50.07 48.51 44.60 24.49
Standard 
deviation
32.47 31.33 39.27 27.55 34.35 0.004
(up to 2) =  
(2 to 7) > (> 10) 
= (no treat.)
n 28 21 38 11 29
Effect   p-value
Time of treatment    0.2057
PTA (initial × final) < 0.0001
Time of treat. × PTA    0.0111
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In the same study, Inoue et al., evaluated the differ-
ent improvement criteria used in the literature. It was ob-
served that criteria that consider a significant improvement 
in which the patient’s final result is a minimum mild hearing 
loss can measure more accurately a significant increase of 
the individual’s hearing. This is due to fact that, with a mild 
hearing loss, one can often attain a natural adaptation to 
this new condition, with less chance of needing individual 
sound amplifiers or other types of hearing aids. For these 
reasons, we chose to use the same improvement criteria 
that Inoue et al. in this study, which were described in the 
previous section.
We also chose to evaluate the time until the start of 
treatment with corticosteroids as a prognostic factor, and 
the use or not of corticosteroids in the treatment, since this 
is the main and most widespread form of therapy used today 
in ISSHL, even though doubts about its effectiveness remain.
The mean rates of absolute and relative recovery in 
this sample were respectively, 23.7 dB and 37.2%. A total 
of 57.5% of patients had some type of improvement and 
only 27.6% showed significant improvement, i.e., at the end 
of the follow-up, these patients had mild hearing loss or 
normal hearing (full improvement = 15.7%). Cvorovic et al. 
in 2008 studied 541 patients with ISSHL and found similar 
rates of recovery of 15.1 dB and 47%.17 However, their rate 
of patients with significant improvement (final PTA < 40 dB) 
was 57%. Xenellis et al., in 2006, found complete recovery 
rates of 37.7% of cases.18 In this study, the absolute rate 
of recovery of the studied population was 24.3 dB and the 
mean final PTA of the population was 47.7 dB, whereas in 
this sample, the mean final PTA was 59.2 dB.
When analyzing the recovery rates of studied patients 
and not considering the time until the start of treatment, it 
was observed that patients treated with corticosteroids did 
not show a statistically significant recovery that was better 
than no treatment, although the analysis shows a trend that 
treatment is better. Wei et al. performed a review of clin-
ical trials and concluded that there is insufficient evidence 
to confirm or rule out the efficacy of corticosteroids in 
ISSHL.19 Other studies, including prospective, randomized, 
double-blind clinical trials suggest the benefit of corticoste-
roid therapy for SSHL. 1.20-24
Corticosteroids are drugs with potent anti-inflammato-
ry and even immunosuppressive action, acting at an ear-
ly stage of the inflammatory cascade. ISSHL occurs due to 
damage to the auditory system, the cause of which is still 
unknown. There are several theories to explain this injury: 
viral infection, ruptured membranes of the inner ear, vas-
cular aggression, autoimmune attack to the vestibule, and 
others,3-6 and all have inflammatory aggression involved in 
their pathogenesis.
Several types of treatment have been devised, with the 
systemic use of corticosteroids being the most often em-
ployed, as it would treat the inflammatory process, which 
is the final pathway of aggression in all these physiopatho-
logical mechanisms. In 2007, in the meta-analysis by Collins 
et al., which included five randomized trials, no evidence 
was found that corticosteroids have better performance 
than placebo or other therapies in ISSHL. However, systemic 
or intratympanic, corticosteroid therapy is the only therapy 
that maintains the recommendation in the latest consensus 
of the American Academy of Otolaryngology in ISSHL.8
The analysis of this sample indicates that different types 
of treatment, not taking into account the time of its onset, 
showed no statistical difference in the degree of improve-
ment. However, groups using corticosteroids were the only 
ones that showed a trend toward greater recovery when 
compared to the ones that effectively had no treatment. 
Patients who received Pentoxifylline were allocated to 
treatment groups, according to the use or nonuse of corti-
costeroids and were therefore assessed, but disregarding its 
use as an effective treatment.
Probst et al.,in a prospective, randomized, double-blind 
study, evaluated 331 cases of ISSHL and acoustic trauma, treat-
ed in three groups with infusions of Pentoxifylline, dextran and 
saline solution, and found no statistical difference in improve-
ment between these medication groups and the placebo group.
In this sample, as in other studies, there was a good cor-
relation between the time until the startof treatment and 
prognosis, as shown by the statistical analysis.17,18,20,25-29
The time until the start of treatment took into account 
the days until the corticosteroid therapy was initiated, 
which in almost all cases, coincided with the day the patient 
was included in our protocol and the initial audiometry. It 
was observed that PTA at the beginning of the follow-up was 
similar in the different ranges of days before the start of 
treatment, indicating that the initial degree of hearing loss 
was similar in the different groups. There was no statistical 
difference in PTA reduction in the three groups that started 
treatment within 10 days.
However, there were lower reductions in PTA for those 
who started treatment after more than 10 days or had no 
treatment. Patients who started treatment before sev-
en days showed reduced PTA with high significance (p < 
0.0001). In addition, it is clearly observed that patients 
who started treatment before 7 days showed better rates 
of absolute and relative recovery when compared to those 
who started treatment in the categories more than 7 and 10 
days. This fact might have influenced the lack of statistical 
significance that occurred when both treatments were com-
pared, as in this analysis, patients who used corticosteroids 
were allocated into a group that did not take into account 
the time until the start of treatment.
There was no statistical difference in recovery rates in 
patients who started treatment with corticosteroids before 
48 hours or in up to 7 days, indicating that the drug has 
similar efficacy if started within 7 days. Huy et al. found 
no benefit with early treatment when compared to individ-
uals that started corticosteroid therapy after 2 or even 3 
to 7 days. The same study, however, did not evaluate any 
patient that started treatment with corticosteroids after 7 
days. Few analyses found no correlation between time of 
start of treatment and prognosis.13,30
Although the statistical data indicate a significant influ-
ence of the time until the start of treatment with cortico-
steroids as an important prognostic factor in the analysis of 
these patients, there is a point that cannot be ignored.
According to Mattox et al., one to two thirds of pa-
tients with ISSHL show spontaneous improvement without 
treatment, a figure that is close to our improvement rate 
of 57.5%. When considering that patients who started treat-
ment and, in this case, had the initial audiometry after 10 
days of evolution, this can lead us to think that these pa-
tients have already undergone a significant period in which 
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there have been partial improvement in audiometric thresh-
olds, and, thus, the potential for improvement in these pa-
tients becomes smaller, which impairs the analysis of the 
real influence of corticosteroids in this category.
This is confirmed by the study of Ito et al. that evaluated 
90 patients with ISSHL and which group of patients showed 
improvement of more than 50% in hearing thresholds in the 
first 2 weeks of evolution and showed better final hearing 
recovery.31 This shows that many patients have a significant 
recovery of thresholds in the first and second weeks, mak-
ing those treated after 10 days, which have already shown 
some recovery, have a lower potential for hearing gain than 
those assessed at onset or, those who have not had signifi-
cant recovery of thresholds fail to do so successfully. In ad-
dition, patients who start treatment and evaluation in early 
days of the picture may not be necessarily improving due 
to treatment itself, as the rates of spontaneous recovery, 
mentioned before, are close to the rates of improvement in 
treated patients.
As it is not possible to detect the specific etiology 
for each individual with ISSHL, these patients will possi-
bly have distinct etiologies, and this factor will certainly 
compromise the analysis and final comparison of hearing 
recovery in these individuals. There are still many ques-
tions regarding the pathogenesis of ISSHL that need to be 
clarified scientifically.
Conclusion
In this study there was no statistically significant improve-
ment in hearing recovery rates among individuals with ISSHL 
treated or not with corticosteroids, in general. However, 
when this treatment was instituted within seven days of on-
set, the use of corticosteroids was significantly better in 
relation to recovery of hearing thresholds.
Conflicts of interest 
The authors declare no conflicts of interest.
References
1.  Wilson WR, Byl FM, Laird N. The efficacy of steroids in the 
treatment of idiopathic sudden hearing loss.A double blind 
clinical study. Arch Otolaryngol. 1980;106:772-6.
2.  Byl FM Jr. Sudden hearing loss: eight years experience and sug-
gested prognostic table. Laryngoscope. 1984;94:647-61.
3.  Schuknecht HF. The pathology of sudden deafness. Acta Otolar-
yngol Stockh. 1973;76:75-97.
4.  Wilson WR, Veltri RW, Laird N, Sprinkle PM. Viral and epidemi-
ologic studies of idiopathic sudden hearing loss. Otolaryngol 
Head Neck Surg. 1983;91:653-8.
5.  Simmons FB. Theory of membrane breaks in sudden hearing 
loss. Arch Otolaryngol. 1968;88:41-8.
6.  Stokroos RJ, Albers FWJ, Tenvergert EM. Antiviral treatment 
of idiopathic; sudden sensorineural hearing loss: a prospec-
tive, randomized, double-blind clinical trial. Acta Otolaryngol 
(Stockh).1998;18:488-95.
7.  Conlin AE, Parnes LS. Treatment of sudden sensorineural hear-
ing loss: a Metanalysis. Arch Otolaryngol Head Neck Surg. 
2007;133:582-6.
8. Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, 
Schwartz SR, Barrs DM, et al. Clinical Practice Guideline :Sud-
den Hearing Loss. Otolaryngol Head Neck Surg. 2012;146:S1.
9.  Fisch U. Management of sudden deafness. Otolaryngol Head 
Neck Surg. 1983;91:3-8.
10.  Probst R, Tschopp K, Ludin E, Kellerhals B, Podvinec M, Pfaltz 
CR. A randomized, double-blind, placebo controlled study of 
dextran/pentoxifylline medication in acute acoustic trauma and 
sudden hearing loss. Acta Otolaryngol Suppl. 1992;112:435-43.
11.  Hultcrantz E, Stenquist M, Lyttkens L. Sudden deafness: a ret-
rospective evaluation of dextran therapy. ORL J Otorhinolaryn-
gol Relat Spec. 1994;56:137-42.
12.  Mattox DE, Simmons FB. Natural history of sudden sensorineu-
ral hearing loss. Ann Otol Rhinol Laryngol. 1977;86:463-80.
13.  Huy PT, Sauvaget E. Idiopathic sudden sensorineural hearing loss 
is not an otologic emergency. Otol Neurotol. 2005;26:896-902.
14.  Kronemberg J, Almagor M, Bendet E, Kushnir D. Vasoactive ther-
apy versus placebo in the treatment of sudden hearing loss: a 
double¬blind clinical study. Laryngoscope. 1992;102:65-8.
15.  Nosrati¬Zarenoe R, Arlinger S, Hultcrantz E. Idiopathic sudden 
sensorineural hearing loss: results drawn from the Swedish na-
tional database. Acta Otolaryngol. 2007;127: 1168-75.
16.  Inoue DP, Bogaz EA, Barros F, Penido NO. Comparison Of Hear-
ing Recovery Criteria In Sudden Sensorineural Hearing Loss. 
Braz J Otorhinolaryngol. 2012;78:42-8.
17.  Cvorovic L, Deric D, Probst R, Hegemann S. Prognostic Model 
for Predicting Hearing Recovery in Idiopathic Sudden Sensori-
neural Hearing Loss. Otol Neurotol. 2008;29:464-9.
18.  Xenellis J, Karapatsas I, Papadimitriou N, Nikolopoulos T, Maragou-
dakis P, Tzagkaroulakis M, et al. Idiopathic sudden sensorineural 
hearing loss: prognostic Factors. J Laryngol Otol. 2006;120:718-24.
19.  Wei BP, Mubiru S, O’Leary S. Steroids for idiopathic sudden sensori-
neural hearing loss. Cochrane Database Syst Rev. 2006;(1):CD003998.
20.  Chang NC, KuenYao HO, WenReiKuo. Audiometric patterns and 
prognosis in Sudden sensorineural hearing loss in Southern Tai-
wan. Otolaryngol Head Neck Surg. 2005;133:916-22.
21.  De Kleyn A. Sudden complete or partial loss of function of the 
octavus system in apparently normal persons. Acta Otolaryn-
gol. 1944;32:407-29.
22.  Slattery WH, Fisher LM, Iqbal Z, Liu N. Oral steroid regimens 
for idiopathic sudden sensorineural hearing loss. Otolaryngol 
Head Neck Surg. 2005;132:5-10.
23.  Stokroos RJ, Albers FWJ. Therapy of idiopathic sudden senso-
rineural hearing loss.A review of the literature. Acta Otorhino-
laryngol Belg. 1996;50:77-84.
24.  Labus J, Breil J, Stutzer H, Michel O. Meta-analysis for the 
effect of medical therapy vs. placebo on recovery of idiopathic 
sudden hearing loss. Laryngoscope. 2010;120:1863-71.
25.  Shaia FT, Sheehy JL. Sudden sensorineural hearing impairment: 
a report of 1,220 cases. Laryngoscope. 1976;86:389-98.
26.  Narozny W, Kuczkowski J, Kot J, Stankiewicz C, Sicko Z, Mi-
kaszewski B. Prognostic Factors in Sudden Sensorineural Hear-
ing Loss: Our Experience and a Review of the Literature. Ann 
Otol Rhinol Laryngol. 2006;115:553-8.
27.  Mamak A, Yilmaz S, Cansiz H, Inci E, Guclu E, Derekoylu L. A 
study of prognostic factors in sudden hearing loss. Ear Nose 
Throat J. 2005;84:641-4.
28.  Psifidis AD, Psillas GK, Daniilidis JC. Sudden sensorineural 
hearing loss: Long-term follow-up results. Otolaryngol Head 
Neck Surg. 2006;134: 809-15.
29.  Penido NO, Ramos HVL, Barros FA, Cruz OLM, Toledo RN. Fa-
tores clínicos, etiológicos e evolutivos da audição na surdez 
súbita. Braz J Otorhinolaryngol. 2005;71:633-8.
30.  Ceylan A, Celenk F, Kemaloglu YK, Bayazit YA, Goksu N, Ozbilen 
S. Impact of prognostic factors on recovery from sudden hear-
ing loss. J Laryngol Otol. 2007;121:1035-40.
31.  Ito S, Fuse T, Yokota M, Watanabe T, Inamura K, Gon S, et al. 
Prognosis is predicted by early hearing improvement in pa-
tients with idiopathic sudden sensorineural hearing loss. Clin 
Otolaryngol Allied Sci. 2002;27:501-4.
